Spotlight – scratching the surface of the urticaria pipeline
Catalysts from several late-stage projects including those from Astrazeneca, Sanofi, Allakos and Celldex aim to shake up the market.
AAIC 2023 – Lilly downplays tau testing needs
But subgroup analyses from Trailblazer-Alz 2 show that earlier is better for donanemab.
Argenx surges after hit in nerve disorder
The Belgian group is riding high as investors look for future successes in other inflammatory diseases.
Bridgebio finally gets its cardiomyopathy win
A convincing hit puts approval, and potentially partnerships, on the table.
Big readouts ahead for small biotechs
Nash data are due for Terns and Inventiva, as Marinus aims to expand its rare disease offering.
Astrazeneca and Daiichi’s big reveal disappoints
High level results on datopotamab raise safety and efficacy concerns, putting billion-dollar sales forecasts at risk.
Big biotech's upcoming clinical priorities
Key catalysts lie ahead for Amgen, Argenx, Point Biopharma and Novo Nordisk.